Search the Newsreel

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Capricor Therapeutics, Inc. (CAPR) following a significant stock price drop after the FDA released critical briefing documents concerning Capricor's cell therapy for Duchenne muscular dystrophy. The FDA documents questioned the scientific justification of Capricor's data measurement methods …

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. for alleged materially false and/or misleading statements regarding changes to their Deramiocel clinical trial analysis plan without FDA agreement. Investors who purchased Capricor securities between December 17, 2025, and July 26, …

Capri Global Capital launches Nayanthara-led brand campaign

Capri (NYSE:CPRI) Issues FY 2027 Earnings Guidance

Capri (CPRI) Earnings Date and Reports 2026 $CPRI

Capri Holdings Limited 2027 Q1 - Results - Earnings Call Presentation (NYSE:CPRI) 2026-08-05

Capri Holdings Ltd (CPRI) reported its Q1 2027 earnings, beating EPS expectations by 66.7% with $0.67 against an estimated $0.40. Revenue also surpassed estimates, reaching $769M compared to the $753M estimate. Despite trimming revenue guidance due to inventory delays, softer EMEA demand, and currency …

Capri (NYSE:CPRI) Releases Earnings Results, Beats Expectations By $0.27 EPS

Capri Global Capital to host analyst meet on Aug 10

Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis …

Capri Holdings earnings on deck as luxury turnaround tested

Capri Holdings, owner of Michael Kors and Jimmy Choo, is set to release its Q1 fiscal 2027 earnings, with analysts anticipating declines in EPS and revenue year-over-year. Investors will be closely watching the health of the Michael Kors brand, which accounts for 83% of …

CAPRICOR THERAPEUTICS, INC. (CAPR) INVESTOR ALERT Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) …

Capricor Therapeutics (CAPR) to Post Earnings on Tuesday

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to release its Q2 2026 earnings after market close on Tuesday, August 11th, with analysts forecasting a loss of $0.58 per share and revenue of $2.08 million. The company's stock has seen a significant decline due to regulatory concerns …

Capri Q1 2027 Earnings Preview

* Capri (CPRI [https://seekingalpha.com/symbol/CPRI]) is scheduled to announce Q1 earnings results on Wednesday, August 5th, before market open. * The consensus EPS Estimate is $0.40 [https://seekingalpha.com/symbol/CPRI/earnings/estimates] (-20.0% Y/Y) and the consensus Revenue Estimate is $752.85M (-5.5% Y/Y). * Over the last 2 years, CPRI …

CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors

A class action lawsuit has been filed against Capricor Therapeutics, Inc. and its executives for securities fraud following a significant 64% stock drop. The lawsuit alleges Capricor made false statements regarding Deramiocel and the integrity of its clinical data, specifically concerning undisclosed changes to …

Capricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics.

Capricor Therapeutics' deramiocel for Duchenne muscular dystrophy faced a decisive 9-3 rejection from an FDA advisory committee, despite its Phase 3 study meeting primary and secondary endpoints. The failure stemmed not from the therapy's scientific signal, but from unresolved statistical issues and concerns over …

Dimensional Fund Advisors LP Increases Position in Capri Holdings Limited $CPRI

Dimensional Fund Advisors LP has increased its stake in Capri Holdings Limited by 34.7% in the first quarter, now owning 2,165,618 shares valued at $38.15 million. Other institutional investors have also adjusted their positions in Capri. The company's stock has seen recent movement, and …

Capricorn Metals (ASX:CMM) Extends Rally as Gold Stocks Continue to Command Investor Attention

INVESTOR ALERT: Securities Class Action Filed Against Capricor Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased stock between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis plan for …

CAPR Class Action Lawsuit FILED: Capricor Therapeutics Sued for Securities Fraud after Stock Drops 64% Leading to Securities Fraud Case – Investors Urged to Contact BFA Law

A class action lawsuit has been filed against Capricor Therapeutics, Inc. for securities fraud, alleging the company made false statements about its product Deramiocel and the integrity of its clinical data, leading to a significant stock drop. The lawsuit claims Capricor failed to disclose …

RA Capital discloses 3.0M-share Capricor stake in Schedule 13G filing (CAPR)

RA Capital Healthcare Fund, advised by RA Capital Management, has reported a beneficial ownership of 3,014,183 shares of Capricor Therapeutics, Inc. common stock, representing 5.2% of the outstanding shares. While RA Capital has been delegated sole power to vote and dispose of these shares, …

Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis …

Law Offices of Frank R. Cruz Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz has filed a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) on behalf of shareholders who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges the company made misleading statements regarding changes to …

Deadline Soon: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz is reminding Capricor Therapeutics, Inc. (CAPR) investors of a September 28, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit alleges that Capricor made misleading statements between December 17, 2025, and July 26, 2026, …

CAPR Investigation Notice: Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Law

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop. If you invested in Capricor Therapeutics securities, you are encouraged …

Capricor Investor News: If You Have Suffered Losses in Capricor Therapeutics Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Aug. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially …

Capri Holdings Number of Employees 2026 | Employee Count & Headcount Data

Capri Holdings (CPRI) had approximately 11,235 employees worldwide as of March 2026, representing a 13.9% decline since 2023. The company is actively hiring, with 766 active job postings in 2026, and its workforce is concentrated in North America (39.9%), Southern Europe (14.8%), and East …

Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Hold Rating

Maxim Group has reiterated its Hold rating on Capricor Therapeutics (CAPR.US). The article does not provide specific details on the reasons for this rating or any financial metrics.

Wall Street Zen Downgrades Capricor Therapeutics (NASDAQ:CAPR) to Strong Sell

Wall Street Zen has downgraded Capricor Therapeutics (NASDAQ:CAPR) to a "strong sell" rating following a series of negative developments. The FDA's advisory committee voted against the effectiveness of Capricor's lead candidate, Deramiocel, and the company is facing securities-fraud investigations and shareholder lawsuits. Consequently, other …

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

Robbins LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor misled investors regarding the FDA approval prospects for its lead product …

CAPR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging that the company made materially false or misleading statements regarding changes to the statistical analysis plan for Deramiocel and the FDA's lack of agreement to these changes, creating a significant …

Vanguard Portfolio Management (CPRI) discloses 6.6M Capri Holdings shares in 5.75% stake filing

Vanguard Portfolio Management has disclosed a 5.75% stake in Capri Holdings Ltd, beneficially owning 6,602,820 shares. This filing indicates that Vanguard has sole dispositive power over all these shares and sole voting power over 180,080 shares. The ownership is attributed to Vanguard funds and …

Form 4 Capri Holdings Ltd For: 31 July By Investing.com

This article announces the filing of Form 4 for Capri Holdings Ltd, specifically for the period ending July 31st. It briefly states the company name and filing date, indicating a regulatory financial disclosure. The article was published on July 31, 2026, and is from …

Director equity awards at Capri Holdings (NYSE: CPRI) show RSU vesting and grant

Capri Holdings director Judy Gibbons reported equity award activity, including the vesting of 8,426 restricted share units (RSUs) which converted into ordinary shares, with 3,961 shares withheld for tax obligations at $15.83 per share. She also received a new grant of 11,055 RSUs that …

Capri Holdings Ltd (CPRI) director has RSUs vest and receives award

Capri Holdings Ltd director Jean Tomlin reported equity compensation activity on July 29, 2026. This involved 8,426 Restricted Share Units (RSUs) vesting and converting into ordinary shares, with 3,961 shares withheld for tax obligations at $15.83 per share. Tomlin also received a new grant …

Capri Holdings (NYSE: CPRI) director converts 8,426 RSUs, gets 11,055 new RSUs

Capri Holdings director Mahesh Madhavan converted 8,426 restricted share units (RSUs) into ordinary shares, increasing his direct holdings to 19,204 shares. He also received a new grant of 11,055 RSUs, which will vest by July 29, 2027, or the next annual shareholder meeting. These …

Capricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy

An FDA advisory committee voted 9-3 that the available evidence does not support the effectiveness of Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. While this recommendation is non-binding, the FDA will consider it as part of the Biologics License Application (BLA) review, with the …